In addition to the question of how to classify the latest test results on benzoyl peroxide (BPO) preparations used in acne treatment, the results of clinical studies on bimekizumab and new drug candidates such as vilobelimab and LAD191 in hidradenitis suppurativa (HS) were presented.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Type 2 diabetes: sarcopenia and frailty
How can the breakdown of skeletal muscles be stopped?
- Cholangiocarcinoma
Modern molecular diagnostics and targeted therapy options
- Treatment resistant depression
Esketamine nasal spray as monotherapy? New for treatment-resistant depression
- Analysis of SNVCS data from the period 2005-2022
TBE vaccination for children and adolescents in Switzerland
- Tuberculosis
Detecting diabetes in TB patients early and efficiently
- Trichophyton indotineae
Terbinafine-resistant dermatophytoses are on the rise in Central Europe
- Peristomal skin health
Focus on preventive care options
- Disease-modifying therapies for ATTR-CM